secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001104659-26-057524
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tvardi Q1 net loss narrows to $6.8M; TTI-109 data due June, TTI-101 HCC data 2H 2026
--------------------------------------------------------------------------------

- Net loss of $6.8M ($0.73 per share) vs $9.6M ($3.72) in Q1 2025; R&D spend rose to $4.9M.
- Cash, cash equivalents and ST investments $25.0M at March 31, 2026; runway through Q4 2026.
- TTI-109 Phase 1 healthy volunteer topline data and development strategy expected June 2026.
- TTI-101 Phase 2 HCC topline data on track for 2H 2026; IPF fibrosis score reduction 9.4% vs 2.4% placebo.
- TTI-109 is a next-generation STAT3 prodrug designed for improved tolerability vs TTI-101.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465926057524/0001104659-26-057524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465926057524/tm2613977d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-057524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer